Osaka, Japan

Yasufumi Kaneda

This inventor holds 25 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 12 EPO patents, primarily in Stem Cell Therapy. Top assignees: Anges Mg, Inc., Osaka University, Genomidea Inc.. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasufumi Kaneda. Retrieved from https://idiyas.com/inventor/yasufumi-kaneda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 80.0

 

 

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 198(Granted Patents)


Location History:

  • Minoh, JP (2007 - 2008)
  • Mino, JP (2009)
  • Minoo, JP (2010)
  • Osaka, JP (2002 - 2021)
  • Suita, JP (2010 - 2021)

Company Filing History:


Years Active: 2002-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Stem Cell Recruitment
Tissue Regeneration
Cancer Treatment
Anticancer Agents
Biological Molecules
Gene Transfer
Vascular Growth
Skin Ulcer Treatment
RNA Vaccine
DNA Vaccine
Therapeutic Agents
Pharmaceutical Preparations
25 patents (USPTO):Explore Patents

Title: Innovations in Tissue Regeneration: The Patents of Yasufumi Kaneda

Introduction

Yasufumi Kaneda, a prominent inventor based in Osaka, Japan, has made significant contributions to the field of medical science through his innovative patents. With a total of 25 patents to his name, Kaneda's work primarily focuses on methods for enhancing tissue regeneration and harnessing functional cells for therapeutic applications.

Latest Patents

Among Kaneda's latest patents is the "Method for collecting functional cells in vivo with high efficiency." This innovative approach utilizes biologically low invasive vessels filled with biological factors that mobilize specific functional cells within the body. These vessels can be implanted in the body, allowing for the collection of functional cell populations after their mobilization. Alternatively, cells can be directly extracted from the indwelled vessels.

Another groundbreaking patent includes the "Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood." This research demonstrated that intravenous administration of HMGB-1 and S100A8 significantly promoted skin ulcer healing through the recruitment of bone marrow-derived cells. Furthermore, in studies involving cerebral infarction model mice, HMGB-1 treatment not only led to the detection of bone marrow-derived cells expressing nerve cell markers in the brain but also exhibited a marked reduction in the size of cerebral infarcts. The survival rates post-cerebral infarction improved in mice treated with HMGB-1, highlighting the vital role of bone marrow pluripotent stem cells in bone fracture healing as well.

Career Highlights

Kaneda’s illustrious career includes important roles at notable institutions such as Anges Mg, Inc., and Osaka University. His dedication to research has led to numerous advancements in the understanding of cellular behavior and regenerative medicine, making a lasting impact in the biomedical field.

Collaborations

Throughout his career, Yasufumi Kaneda has collaborated with esteemed colleagues, including Katsuto Tamai and Ryuichi Morishita. These partnerships have fostered an environment of innovative thought and advanced research, contributing to the success of his patents and the wider medical community.

Conclusion

Yasufumi Kaneda's work continues to push the boundaries of science with his innovative approaches to tissue regeneration and cell mobilization. His extensive patent portfolio reflects his commitment to advancing medical treatments and improving patient outcomes. Through collaboration and dedication, Kaneda exemplifies the spirit of innovation that drives progress in the field of biomedical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…